Osimertinib

The FDA granted breakthrough therapy designation to osimertinib for adjuvant treatment of certain patients with early-stage non-small cell lung cancer, according to the agent’s manufacturer.

In the first-line setting, osimertinib and gefitinib as combination therapy for the treatment of EGFR-mutated non-small cell lung cancer is tolerable, according to findings presented at the virtual ASCO annual meeting.

Among patients with non-small cell lung cancer who harbor MET exon 14 skipping mutations, or METex14+, savolitinib demonstrated tolerability and anti-tumor activity, according to findings from a phase 2 study presented at the virtual ASCO annual meeting.

In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, shares his perspective on the results from the ADAURA trial, a “potentially paradigm-shifting phase 3 study.”

In this video, Julia K. Rotow, MD, medical oncologist at the Dana-Farber Cancer Institute, discusses presentations in lung cancer from the virtual ASCO annual meeting.

In this video, Nathan A. Pennell, MD, PhD, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, discusses presentations in lung cancer that he found interesting from this year’s virtual ASCO Annual Meeting.

Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

Osimertinib demonstrated “overwhelming efficacy” for the adjuvant treatment of patients with stage IB, II and IIIA epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection, according to a press release issued by the agent’s manufacturer.

First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non-small cell lung cancer, according to results from the randomized phase 3 FLAURA trial presented at European Society for Medical Oncology Asia Congress and simultaneously published in The New England Journal of Medicine.

Lung Cancer Awareness Month — observed every November — is intended to educate the public about the potential causes and risk factors of the disease.